Tenofovir Approved for Treatment of Chronic Hepatitis B in Adults
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Tenofovir Approved for Treatment of Chronic Hepatitis B in Adults

FOSTER CITY, Calif -- August 12, 2008 -- The US Food and Drug Administration has granted marketing approval for tenofovir disoproxil fumarate (Viread) for the treatment of chronic hepatitis B.

Tenofovir disoproxil fumarate is also indicated for the treatment of chronic hepatitis B in adults. The drug is administered as a once-daily tablet and works by blocking hepatitis B virus DNA polymerase.

"[Tenofovir] will be an important new treatment option and its approval represents a significant step forward in the fight against chronic hepatitis B," said Ira Jacobson, MD, Division of Gastroenterology and Hepatology, Weill Cornell Medical College, New York, New York.

The approval is based on data from 2 ongoing, randomised, double-blind, phase 3 clinical trials which compared tenofovir disoproxil fumarate to adefovir dipivoxil over 48 weeks of treatment. Results from both studies show that a significantly greater percentage of patients with chronic hepatitis B who received tenofovir disoproxil fumarate achieved a complete response to treatment compared with those who received adefovir dipivoxil.

SOURCE: Gilead Sciences, Inc.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities